JP7887666B2 - 抗体に結合して中和抗体を阻害するための組成物および方法 - Google Patents

抗体に結合して中和抗体を阻害するための組成物および方法

Info

Publication number
JP7887666B2
JP7887666B2 JP2022505585A JP2022505585A JP7887666B2 JP 7887666 B2 JP7887666 B2 JP 7887666B2 JP 2022505585 A JP2022505585 A JP 2022505585A JP 2022505585 A JP2022505585 A JP 2022505585A JP 7887666 B2 JP7887666 B2 JP 7887666B2
Authority
JP
Japan
Prior art keywords
protein
aav
modified
mycoplasma
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022505585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542294A5 (cg-RX-API-DMAC7.html
JP2022542294A (ja
Inventor
チョンウェン リー
チャールズ アスクー
ブライアン クールマン
デーヴィッド フォレスト シーカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2022542294A publication Critical patent/JP2022542294A/ja
Publication of JP2022542294A5 publication Critical patent/JP2022542294A5/ja
Priority to JP2025139669A priority Critical patent/JP2026000908A/ja
Application granted granted Critical
Publication of JP7887666B2 publication Critical patent/JP7887666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
JP2022505585A 2019-08-01 2020-07-31 抗体に結合して中和抗体を阻害するための組成物および方法 Active JP7887666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139669A JP2026000908A (ja) 2019-08-01 2025-08-25 抗体に結合して中和抗体を阻害するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881765P 2019-08-01 2019-08-01
US62/881,765 2019-08-01
PCT/US2020/044559 WO2021022187A1 (en) 2019-08-01 2020-07-31 Compositions and methods for binding antibodies and inhibiting neutralizing antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139669A Division JP2026000908A (ja) 2019-08-01 2025-08-25 抗体に結合して中和抗体を阻害するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022542294A JP2022542294A (ja) 2022-09-30
JP2022542294A5 JP2022542294A5 (cg-RX-API-DMAC7.html) 2023-08-01
JP7887666B2 true JP7887666B2 (ja) 2026-07-10

Family

ID=74230547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022505585A Active JP7887666B2 (ja) 2019-08-01 2020-07-31 抗体に結合して中和抗体を阻害するための組成物および方法
JP2025139669A Pending JP2026000908A (ja) 2019-08-01 2025-08-25 抗体に結合して中和抗体を阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139669A Pending JP2026000908A (ja) 2019-08-01 2025-08-25 抗体に結合して中和抗体を阻害するための組成物および方法

Country Status (9)

Country Link
US (1) US20220260563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4007768A4 (cg-RX-API-DMAC7.html)
JP (2) JP7887666B2 (cg-RX-API-DMAC7.html)
CN (1) CN114514239A (cg-RX-API-DMAC7.html)
AU (1) AU2020319880B2 (cg-RX-API-DMAC7.html)
CA (1) CA3149679A1 (cg-RX-API-DMAC7.html)
IL (1) IL290219A (cg-RX-API-DMAC7.html)
MX (1) MX2022001425A (cg-RX-API-DMAC7.html)
WO (1) WO2021022187A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152008A (ko) * 2021-02-03 2023-11-02 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 단백질 m 유사체 및 융합 단백질 및 이들의 항체 기능 억제 용도
WO2023125974A1 (zh) * 2021-12-31 2023-07-06 广州国家实验室 mRNA疫苗
CN115047188A (zh) * 2022-06-10 2022-09-13 上海鼎新基因科技有限公司 一种抗腺相关病毒中和抗体的检测方法
CN122127433B (zh) * 2026-04-29 2026-07-17 中国海洋大学 一种抗原表位多肽及其制备的牙鲆mAChR3特异性抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117057A2 (en) 2014-01-31 2015-08-06 The Scripps Research Institute Protein m related immunoglobulin-binding polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
EP2782596A4 (en) * 2011-11-22 2015-07-29 Philadelphia Children Hospital VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
US9593150B2 (en) * 2012-07-16 2017-03-14 The Scripps Research Institute Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
CN107002096A (zh) * 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
CA3001941A1 (en) * 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
DE102016123859B3 (de) * 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117057A2 (en) 2014-01-31 2015-08-06 The Scripps Research Institute Protein m related immunoglobulin-binding polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GROVER RK. et al.,A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union,Science,2014年,vol. 343,pp. 656-660 + Supplementary Materials
SAWITRI KN. et al.,Investigating the effect of mutation on the thermo stability of GB1 protein,Journal of Physics: Conf. Series,2018年,vol. 1011,012084,doi :10.1088/1742-6596/1011/1/012084

Also Published As

Publication number Publication date
EP4007768A1 (en) 2022-06-08
JP2026000908A (ja) 2026-01-06
AU2020319880B2 (en) 2026-08-13
CN114514239A (zh) 2022-05-17
CA3149679A1 (en) 2021-02-04
AU2020319880A1 (en) 2022-03-17
KR20220053575A (ko) 2022-04-29
US20220260563A1 (en) 2022-08-18
WO2021022187A1 (en) 2021-02-04
IL290219A (en) 2022-03-01
EP4007768A4 (en) 2023-11-15
MX2022001425A (es) 2022-05-02
JP2022542294A (ja) 2022-09-30

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260623

R150 Certificate of patent or registration of utility model

Ref document number: 7887666

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150